Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2020
Equity [Abstract]  

On February 10, 2020, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend was paid on March 6, 2020 to stockholders of record on February 25, 2020. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of March 31, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At March 31, 2020, 1,219,583 shares remained available for issuance under the 2016 Plan.
The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
  Shares Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2019 957,682    $ 7.34   
Vested (97,861)   7.53   
Nonvested at March 31, 2020
859,821    7.32   

Accumulated Other Comprehensive Loss
The changes in accumulated other comprehensive loss by component for the first three months of 2020 were as follows (in thousands):
  Foreign Currency Translation Adjustment Unrealized Losses on Available-For-Sale Investments Total
Balance, December 31, 2019 $ (1,245)   $ (19)   $ (1,264)  
Other comprehensive loss (222)   (87)   (309)  
Balance, March 31, 2020
$ (1,467)   $ (106)   $ (1,573)